EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE

Keshu Zhou, Tingyu Wang, Ling Pan, Wei Xu, Jie Jin, Wei Zhang, Yu Hu, Jianda Hu, Ru Feng, Ping Li, Zhougang Liu, Peng Liu und 15 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05823-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Keshu Zhou und 26 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Piperidines, Adenine, Pyrimidines, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeiGene USA, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has different epidemiology in Chinese vs. Western patients, but there are few studies of CLL/SLL in large populations of Chinese patients. ALPINE is a global phase 3 trial investigating Bruton tyrosine kinase inhibitors zanubrutinib vs. ibrutinib to treat relapsed/refractory (R/R) CLL/SLL. Here we report results from the subgroup of Chinese patients. Adults with R/R CLL/SLL were randomized 1:1 to receive zanubrutinib (160 mg twice-daily) or ibrutinib (420 mg once-daily) until disease progression or unacceptable toxicity. Endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Data were analyzed descriptively. Ninety patients were randomized in China (zanubrutinib, n = 47; ibrutinib, n = 43). Baseline characteristics were balanced between groups, with fewer male patients in the zanubrutinib vs. ibrutinib group (55.3% vs. 69.8%). Median age was 60.5 years, 11% had del(17p) mutation, and 32% had tumor protein 53 ( TP53 ) mutation. With median 25.3 months follow-up, ORR was 80.9% with zanubrutinib vs. 72.1% with ibrutinib. PFS was improved with zanubrutinib vs. ibrutinib (HR = 0.34 [95% CI, 0.15, 0.77]), and the HR for OS was 0.45 (95% CI, 0.14, 1.50). Rates of Grade ≥ 3 treatment-emergent adverse events (TEAEs; 64.4% vs. 72.1%), AEs leading to discontinuation (6.4% vs. 14.0%), and serious TEAEs (35.6% vs. 51.2%) were lower with zanubrutinib vs. ibrutinib. Zanubrutinib demonstrated improved ORR, PFS, and OS vs. ibrutinib and a more favorable safety profile in patients with R/R CLL/SLL in China. These results are consistent with the full global population of ALPINE. ClinicalTrials.gov: NCT03734016, registered November 7, 2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesAdeninePyrimidinesLeukemia, Lymphocytic, Chronic, B-CellPyrazolesHumansMaleFemaleMiddle AgedAgedChinaAdultAged, 80 and overProtein Kinase InhibitorsTreatment OutcomeProgression-Free SurvivalAgammaglobulinaemia Tyrosine KinaseDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Chinese populationChronic lymphocytic leukemiaIbrutinibSmall lymphocytic lymphomaZanubrutinib

Substanzen

PiperidinesibrutinibAdeninePyrimidineszanubrutinibPyrazolesProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine Kinase

Autor:innen und Institutionen

  • Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • National Clinical Research Center for Hematological Disorders, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union M…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • West China Hospital, Sichuan University, Sichuan, China.
  • Jiangsu Province Hospital, Zhejiang, China.
  • The First Hospital of Zhejiang Province, Zhejiang, China.

Förderung

  • BeiGene USA, Inc.

Zitieren

APA

Zhou, K., Wang, T., Pan, L., Xu, W., Jin, J., Zhang, W., Hu, Y., Hu, J., Feng, R., Li, P., Liu, Z., Liu, P., Jing, H., Gao, S., Zhang, H., Yu, K., Wang, Z., Zhu, X., Sun, Z., …, & Qiu, L. (2024). Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. Annals of Hematology. https://doi.org/10.1007/s00277-024-05823-8

Vancouver

Zhou K, Wang T, Pan L, Xu W, Jin J, Zhang W, et al. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. Annals of Hematology. 2024. doi:10.1007/s00277-024-05823-8

BibTeX
@article{Zhou2024,
  author = {Zhou, Keshu and Wang, Tingyu and Pan, Ling and Xu, Wei and Jin, Jie and Zhang, Wei and Hu, Yu and Hu, Jianda and Feng, Ru and Li, Ping and Liu, Zhougang and Liu, Peng and Jing, Hongmei and Gao, Sujun and Zhang, Huilai and Yu, Kang and Wang, Zhao and Zhu, Xiongpeng and Sun, Zimin and Li, Fei and Yan, Dongmei and Weng, Jianyu and Fu, Lina and Wang, Liping and Salmi, Tommi and Wu, Kenneth and Qiu, Lugui},
  title = {Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05823-8}
}
Kostenlos starten →